Objectives: Colorectal cancer (CRC) is one of the mostcommon gastrointestinal cancers in the world. In the AsiaPacificregion, it is the fastest emerging gastrointestinalcancer. Level of awareness on CRC warning signs and riskfactors in the rural population of Malaysia is reported of verylow. The aim of this study was to assess the level ofknowledge of CRC among the public at medical outpatientclinics in Serdang Hospital. The association between sociodemographicfactors with level of knowledge among therespondents was further studied.Study design: A study was conducted among the non-CRCpatients’ relatives accompanying their relatives to themedical outpatient clinics in Serdang Hospital from 1st Aprilto 31st August 2016. The study was carried out with clustersampling method.Methods: The respondents were assessed using validatedand modified Cancer Awareness Measures (CAM)questionnaire consists of three parts which are knowledgeon warning signs, knowledge on risk factors and sociodemographicfactors. All data were analysed using IBMSPSS Statistics 21.0.Results: Altogether 308 subjects completed thequestionnaires. It was shown high percentage of goodknowledge for warning signs and risk factors of CRC amongthe respondents. A significant association between agegroups and level of income with level of knowledge onwarning signs was observed.Conclusions: The level of knowledge of CRC among thegeneral public in Serdang Hospital was sufficient. Therespondents with higher income or younger age had higherlevel of knowledge regarding CRC.

PURPOSE: REVEL demonstrated improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with docetaxel+ramucirumab versus docetaxel+placebo in 1,253 intent-to-treat (ITT) stage IV non-small cell lung cancer patients with disease progression following platinum-based chemotherapy. Results from the East Asian subgroup analysis are reported. MATERIALS AND METHODS: Subgroup analyses were performed in the East Asian ITT population (n=89). Kaplan-Meier analysis and Cox proportional hazards regression were performed for OS and PFS, and the Cochran-Mantel-Haenszel test was performed for response rate. RESULTS: In docetaxel+ramucirumab (n=43) versus docetaxel+placebo (n=46), median OS was 15.44 months versus 10.17 months (hazard ratio [HR], 0.762; 95% confidence interval [CI], 0.444 to 1.307), median PFS was 4.88 months versus 2.79 months (HR, 0.658; 95% CI, 0.408 to 1.060), and ORR was 25.6% (95% CI, 13.5 to 41.2) versus 8.7% (95% CI, 2.4 to 20.8). Due to increased incidence of neutropenia and febrile neutropenia in East Asian patients, starting dose of docetaxel was reduced for newly enrolled East Asian patients (75 to 60 mg/m², n=24). In docetaxel+ramucirumab versus docetaxel+placebo, incidence of neutropenia was 84.4% versus 72.7% (75 mg/m²) and 54.5% versus 38.5% (60 mg/m²). Incidence of febrile neutropenia was 43.8% versus 12.1% (75 mg/m²) and 0% versus 7.7% (60 mg/m²). CONCLUSION: Results of this subgroup analysis showed a trend favoring ramucirumab+docetaxel for median OS, PFS, and improved ORR in East Asian patients, consistent with ITT population results. Reduction of starting dose of docetaxel in East Asian patients was associated with improved safety.
Asian Continental Ancestry Group* ; Carcinoma, Non-Small-Cell Lung* ; Disease Progression* ; Disease-Free Survival ; Drug Therapy ; Far East ; Febrile Neutropenia ; Humans ; Incidence ; Kaplan-Meier Estimate ; Neutropenia